Relationship of HER2 gene amplification to clinicopathological characteristics and prognosis of salivary gland malignant pleomorphic adenoma

doi:10.19438/j.cjoms.2018.01.003

Abstract

Abstract: PURPOSE: To investigate HER2 gene overexpression or amplification in human salivary malignant pleomorphic adenoma (MPA), and analyze the association between HER2 and tumor clinicopathological characteristics, as well as prognosis, in order to assess its potential as a therapeutic target. METHODS: The expression of HER2 protein was detected by immunohistochemistry in 140 patients with MPA, and the amplification of HER2 gene was determined by fluorescence in situ hybridization for HER2 2+ cases. The clinicopathological data of 140 patients were reviewed. The correlation between HER2 gene amplification and clinicopathological features and prognosis of MPA patients was analyzed using SPSS 16.0 software package. RESULTS: The positive rate of HER2 in 140 patients with MPA was 25%. The positive rate of HER2 in adenocarcinoma subtype of MPA was 40.5% (32/79), which was significantly higher than that of myoepithelial carcinoma subtype MPA (4.9%, 3/61, P<0.05). HER2 positive staining was significantly correlated with gender, histological grade and N stage. Survival analysis showed that overall survival and disease-specific survival were lower in HER2 positive patients. CONCLUSION: Overexpression and amplification of HER2 gene is significantly correlated with the malignant subtype of MPA tumor cells, and suggests a poor prognosis in patients with MPA.

Key words: HER2, Malignant pleomorphic tumor, Differentiation, Target therapy

CLC Number:

R739.8

XIA Liang, WANG Yang, HU Yu-hua, GU Ting, LI Jiang, SHI Hui-min, TIAN Zhen. Relationship of HER2 gene amplification to clinicopathological characteristics and prognosis of salivary gland malignant pleomorphic adenoma[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(1): 12-19.

References

[1] Hashimoto K, Yamamoto H, Shiratsuchi H, et al.HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study[J]. Histopathology, 2012, 60(6B): E131-142.
[2] Tian Z, Li L, Wang L, et al.Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 235-242.
[3] Altemani A, Martins MT, Freitas L, et al.Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression[J]. Histopathology, 2005, 46(6): 635-641.
[4] Guzzo M, Locati LD, Prott FJ, et al.Major and minor salivary gland tumors[J]. Crit Rev Oncol Hematol, 2010, 74(2): 134-148.
[5] Hirsch FR, Varella-Garcia M, Franklin WA, et al.Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas[J]. Brit J Cancer, 2002, 86(9): 1449-1456.
[6] Marx AH, Tharun L, Muth J, et al.HER-2 amplification is highly homogenous in gastric cancer[J]. Hum Pathol, 2009, 40(6): 769-777.
[7] Glisson B, Colevas AD, Haddad R, et al.HER2 expression in salivary gland carcinomas: dependence on histological subtype[J]. Clin Cancer Res, 2004, 10(3): 944-946.
[8] Yan M, Parker BA, Schwab R, et al.HER2 aberrations in cancer: implications for therapy[J]. Cancer Treat Rev, 2014, 40(6): 770-780.
[9] Figueroa-Magalhaes MC, Jelovac D, Connolly RM, et al.Treatment of HER2-positive breast cancer[J]. Breast, 2014, 23(2): 128-136.
[10] Clauditz TS, Reiff M, Gravert L, et al.Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas[J]. Pathology, 2011, 43(5): 459-464.
[11] Williams MD, Roberts DB, Kies MS, et al.Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance[J]. Clin Cancer Res, 2010, 16(8): 2266-2274.
[12] Limaye SA, Posner MR, Krane JF, et al.Trastuzumab for the treatment of salivary duct carcinoma[J]. Oncologist, 2013, 18(3): 294-300.
[13] Lewis JE, Olsen KD, Sebo TJ.Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases[J]. Hum Pathol, 2001, 32(6): 596-604.
[14] Di Palma S, Skálová A, Vanìèek T, et al.Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry[J]. Histopathology, 2005, 46(2): 144-152.
[15] Freitas LL, Araujo VC, Martins MT, et al.Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation[J]. Int J Surg Pathol, 2005, 13(4): 337-342.
[16] Nishijima T, Yamamoto H, Nakano T, et al.Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma[J]. Hum Pathol, 2015, 46(11): 1730-1743.
[17] Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
[18] Kadowaki S, Yatabe Y, Hirakawa H, et al.Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma[J]. Case Rep Oncol, 2013, 6(3): 450-455.
[19] Sharon E, Kelly RJ, Szabo E.Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine[J]. Head Neck Oncol, 2010, 2: 12.
[20] Slamon DJ, Clark GM, Wong SG, et al.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182.
[21] Lee JS, Kwon OJ, Park JJ, et al.Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?[J]. J Oral Maxillofac Surg, 2014, 72(5): 1023-1031.